<?xml version="1.0" encoding="iso-8859-1" ?>
<PASBIO>
    <framesest>
        <predicate lemma="truncate">
            <roleset id="Truncate.01" name="" wordnet="3">
                <roles>
                    <role n="0" descr="cause&#x09;&#x09;&#x09;// mutation //&#x0A;" />
                    <role n="1" descr="entity getting shorter &#x09;// gene products //&#x0A;" />
                    <role n="2" descr="entity removed&#x09;&#x09;// domains, exon, intron //&#x0A;" />
                    <role n="3" descr='break point &#x09;&#x09;/* related to prepositional phrase such as &quot;at&quot;, &quot;prior to&quot; */&#x0A;' />
                </roles>
                <example src="EMBO" no="0">
                    <text>C-terminally truncated Stat5a proteins, truncated at amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">C-terminally truncated Stat5a proteins</arg>
                    <arg n="3">amino acids 762 or 773</arg>
                </example>
                <example src="EMBO" no="1">
                    <text>Specifically, the Stat5a molecule in which the C-terminus was truncated at amino acids 740 or 751 effectively blocked the induction of both CIS and OSM, whereas the C-terminal truncations at amino acids 762 or 773 had no effect on the induction of either gene.</text>
                    <arg n="1">the Stat5a molecule</arg>
                    <arg n="2">C-terminus</arg>
                    <arg n="3">amino acids 740 or 751</arg>
                </example>
                <example src="EMBO" no="2">
                    <text>Therefore, to generate a comparable soluble fragment to IC1-2D/190, PVR was also truncated prior to the PP-motif.</text>
                    <arg n="1">PVR</arg>
                    <arg n="3">the PP-motif</arg>
                </example>
                <example src="EMBO" no="3">
                    <text>To generate this protein, the receptor was truncated prior to two consecutive proline residues (`PP-motif_) present in the junction between domains 2 and 3 (Figure 1).</text>
                    <arg n="1">the receptor</arg>
                    <arg n="3">two consecutive proline residues</arg>
                </example>
                <example src="MEDLINE" no="1">
                    <text>Frameshift SOX9 mutations truncate its two activation domains, while all missense mutations reported to date lie in the high mobility group (HMG) DNA-binding domain.</text>
                    <arg n="0">Frameshift SOX9 mutations</arg>
                    <arg n="2">its two activation domains</arg>
                </example>
                <example src="MEDLINE" no="2">
                    <text>Previous studies using wild-type Encephalomyocarditis virus (EMCV) and Mengo virus, and variants of these viruses genetically engineered to truncate or substitute the poly(C) tracts have produced conflicting data on the role of the poly(C) tract in the virulence of these viruses.</text>
                    <arg n="0">wild-type Encephalomyocarditis virus (EMCV) and Mengo virus, and variants of these viruses</arg>
                    <arg n="1">the poly(C) tracts</arg>
                </example>
                <example src="MEDLINE" no="3">
                    <text>The majority of changes were predicted to truncate the protein through nonsense mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%), although the figures were biased by the methods employed, and, in sequenced areas, approximately 50% of all mutations were missense or in-frame.</text>
                    <arg n="0">nonsense mutations (32%), insertions or deletions (29.6%), or splicing changes (6.2%)</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="MEDLINE" no="4">
                    <text>The putative resulting protein retained the region encoding the structural and functional elements of the amine oxidase but the second and fourth SRCR domains were truncated and the potential BMP-1 cleavage site was not present.</text>
                    <arg n="2">the second and fourth SRCR domains</arg>
                </example>
                <example src="MEDLINE" no="5">
                    <text>To evaluate the role of the N-terminus of M.MspI, 2-hydroxy-5-nitrobenzyl bromide (HNBB) was used to truncate M.MspI between residues 34 and 35.</text>
                    <arg n="0">2-hydroxy-5-nitrobenzyl bromide (HNBB)</arg>
                    <arg n="1">M.MspI</arg>
                    <arg n="3">residues 34 and 35</arg>
                </example>
                <example src="MEDLINE" no="6">
                    <text>Two of these variants result in altered postsynaptic density 95 (PSD95) isoforms that dramatically truncate the protein.</text>
                    <arg n="0">altered postsynaptic density 95 (PSD95) isoforms</arg>
                    <arg n="1">the protein</arg>
                </example>
                <example src="MEDLINE" no="7">
                    <text>Virtually all TSC1 mutations are predicted to truncate the protein product.</text>
                    <arg n="0">TSC1 mutations</arg>
                    <arg n="1">the protein product</arg>
                </example>
                <example src="MEDLINE" no="8">
                    <text>We used a gene-targeting approach in cultured myoblasts to truncate the titin gene so that the kinase domain and other domains downstream of the kinase were not expressed.</text>
                    <arg n="0">a gene-targeting approach</arg>
                    <arg n="1">the titin gene</arg>
                </example>
            </roleset>
        </predicate>
    </framesest>
</PASBIO>
